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Recent studies have identified a family of DNA-binding proteins that share a common DNA-binding and
dimerization domain with the potential to form a helix-loop-helix (HLH) structure. Various HLH proteins can
form heterodimers that bind to a common DNA sequence, termed the E2-box. We demonstrate here that
E2-box-binding B-cell- and myocyte-specific nuclear factors contain subunits which are identical or closely
related to ubiquitously expressed (E12/E47) HLH proteins. These biochemical data suggest a pleiotropic
function for E12/E47-like molecules in mammalian differentiation, similar to the genetically defined function of
daughterless in Drosophia development.
One class of DNA-binding proteins contains a region of
homology that has the potential to form a helix-loop-helix
(HLH) structure preceded by a highly basic region (22); this
region has been shown to contain a DNA-binding and
dimerization domain (12, 22, 29). Certain HLH homo- and
heterodimers bind to a common DNA sequence, termed the
E2-box. The E2-box is present in the immunoglobulin heavy-
and light-chain gene enhancer, the insulin gene enhancer,
and the muscle creatine kinase gene enhancer (4, 7, 19, 20).
In each of these enhancers it plays a crucial role in the
regulation oftissue-specific gene expression. Representative
members of the HLH family that bind the E2-box are E12
(pan-1), E47 (E2-5; pan-2), and E2-2 (16, 22, 24) immuno-
globulin enhancer-binding proteins; MyoD (12), myogenin
(3, 31), and myf-5 (2), three proteins that induce myogenesis;
and daughterless (da) (6, 8-11) and achaete-scute (28),
Drosophila genes that are involved in cell determination and
differentiation. In vitro evidence implies that classes ofHLH
proteins use combinatorial interactions to control tissue-
specific gene expression in various developmental pathways
(21). Class A includes ubiquitously expressed proteins da,
E12, E2-2, and E47. E12 and E47 are differentially spliced
products of the same gene (26b) and share most of their
amino acid sequence. All four proteins have very closely
related HLH motifs. Class B includes tissue-specific pro-
teins, MyoD, myogenin, myf-5, and members ofthe achaete-
scute gene family. Class B proteins bind in vitro with high
affinity to the E2-box as heterodimers with class A proteins.
In addition, there is a class of HLH proteins which lack a
basic region and thus are negative regulators ofDNA binding
(Id, extramacrochaete) (1, 14, 15). To examine whether
HLH heterodimers are also formed in vitro, E2-box-binding
proteins from a variety of cell lines were characterized. We
show here that B-cell- and muscle-specific E2-box-binding
factors contain components that are identical or antigeni-
cally related to the E12/E47 proteins.
MATERIALS AND METHODS
Cell lines. HeLa and LA-N-5 (26) cells were grown in
Dulbecco modified Eagle medium supplemented with 5%
* Corresponding author.
(vol/vol) fetal calf serum. PD31 and WEHI 231 cells were
grown in RPMI medium containing 10% fetal calf serum.
Ba/F and LyD9 were grown in RPMI medium containing
20% fetal calf serum and interleukin-3 (27).
Plasmids. A 2-kb cDNA fragment containing the entire
coding region of E47 was inserted into the XbaI site of the
pBluescript II SK- vector (Stratagene) (28a) for in vitro
transcription with T3 RNA polymerase. A CDM8 vector
containing the 2-kb E47 cDNA insert at its BstXI site was
used for expression in eucaryotic cells (25).
Extract preparation and gel shift assays. Nuclear extracts
were prepared exactly as described by Dignam et al. (13).
Oligonucleotides containing the wild-type monomeric 1xE2
and muscle creatine kinase E2-box sequence were 32p la-
beled (50,000 cpm/ng), and 0.5 ng of DNA probe was
incubated with 3 to 10 ,ug ofnuclear extract. The KE2 probe
was derived from a restriction fragment as described previ-
ously (22). The binding reaction mixtures were incubated at
room temperature for 15 min and contained 10 mM Tris (pH
7.5), 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5%
glycerol, and 0.5 or 1 pug ofpoly(dIC-dIC) as the nonspecific
competitor. The complexes were resolved by electrophore-
sis through 4% polyacrylamide gels containing 50 mM Tris,
0.38 M glycine, and 2 mM EDTA. For competition experi-
ments the conditions were exactly as described above,
except that specific and nonspecific competitor DNAs were
included in the mixture (in the amounts detailed in the figure
legends) prior to the addition of protein. For supershift
assays, nuclear extracts were incubated for 15 min with
antibody prior to incubation with labeled DNA.
In vitro transcription and translation. RNA was synthe-
sized in a 100-,ul reaction for 2 h at 40°C with a substrate of
2 p.g oflinearized DNA and with T3 or T7 RNA polymerase
(Stratagene) in the presence of RNasin (Boehringer Mann-
heim). The RNA was phenol and chloroform extracted once
and ethanol precipitated. The ethanol precipitate was dried
and resuspended in 20 ,ul of water. In vitro translation ofthe
RNAs was done by using a rabbit reticulocyte lysate
(Promega) in a 50-,u reaction with 10% of the synthesized
RNA as a substrate. Proteins were synthesized at 30°C for 1
h. Reaction conditions were as recommended by the manu-
facturer (Promega).
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FIG. 1. Binding of proteins to the E2-box motif. (A) B-cell and myocyte nuclear extracts contain tissue-specific muscle creatine kinase
enhancer E2-box DNA-binding proteins. Lanes: 1, HeLa extract; 2, LA-N-5 extract (neuroblastoma); 3, Jurkat extract (T cell); 4, WEHI 231
extract (mature B cell); 5, C2C12 extract (muscle cell). (B) B-cell- and myocyte-specific proteins bind specifically to the muscle creatine kinase
enhancer E2-box. Lanes: 1, WEHI 231 extract with no competitor added (-); 2, WEHI 231 extract in the presence of 10 ng of unlabeled
wild-type (wt) E2-box competitor DNA; 3, WEHI 231 extract in the presence of 10 ng ofunlabeled mutant (mut) E2-box competitor DNA;
4, C2C12 extract with no competitor DNA added; 5, C2C12 extract in the presence of 10 ng ofunlabeled E2-box competitor DNA; 6, C2C12
extract with 10 ng ofunlabeled mutant E2-box competitor DNA; 7, HeLa extract with no competitor DNA added; 8, HeLa extract with 10
ng ofunlabeled E2-box competitor DNA added; 9, HeLa extract with 10 ng ofunlabeled mutant competitor DNA added. (C) B-cell-specific
DNA-binding proteins bind to the E2-box present in the muscle creatine kinase enhancer and to FE5 and KE2 sequences present in the
immunoglobulin enhancers. Lanes: 1, WEHI 231 extract analyzed by using the E2-box present in the muscle creatine kinase enhancer as a
probe; 2, WEHI 231 extract analyzed by using the E2-box present in the KE2 site ofthe kappa light-chain enhancer as a probe; 3, WEHI 231
extract analyzed by using the E2-box present in the pLE5 site ofthe immunoglobulin heavy-chain enhancer as a probe. MEF, Muscle-specific
complexes; NS, nonspecific DNA-binding proteins.
RESULTS
B-cell-specific E2-box DNA-binding proteins. B-cell-spe-
cific proteins binding to the E-box sites in the immunoglob-
ulin heavy-chain enhancer were first detected by in vivo
methylation protection experiments (7). Previous studies
with low-ionic-strength gel systems failed to detect such
B-cell-specific E2-box-binding proteins in vitro (17, 19).
Recently, tissue-specific E2-box-binding proteins were
found in muscle-derived nuclear extracts (3, 4, 18). To look
for other tissue-specific E2-box-binding proteins, we
screened a wide variety of nuclear extracts by using an
electrophoretic mobility shift assay (EMSA) at high ionic
strength. As demonstrated before (3, 4, 18), muscle-specific
proteins, designated as MEF-1, are present in myocyte
nuclear extracts and bind the E2-box sequence present in the
muscle creatine kinase enhancer (Fig. 1A, lane 5). Nuclear
extracts derived from HeLa cells (lane 1), the T-cell line
Jurkat (23) (lane 3), and the neuroblastoma cell line LA-N-5
(26) (lane 2) did not contain complexes that migrated in a
cell-type-specific manner. However, nuclear extracts de-
rived from a mature B-cell line, WEHI 231, contained two
B-cell-specific complexes, termed BCF1 and BCF2, which
were notfound in extracts ofthe other tested cell types (lane
4). Thus, in addition to myocytes, distinct but tissue-specific
E2-box-binding proteins are present in nuclear extracts
derived from B cells.
To determine whether the B-cell- and myocyte-specific
complexes interact with the E2-box in a specific manner, we
performed a competition analysis. DNA containing the wild-
type E2-box sequence, derived from the muscle creatine
kinase enhancer (GCAGGTGT), did compete for BCF1 and
BCF2 binding (Fig. 1B, lane 2), whereas DNA containing a
mutant E2-box sequence (TACCGTGT) did not compete
(lane 3). Similarly, DNA containing the wild-type E2 se-
quence competed for binding to muscle-specific complexes
(18) (Fig. 1B, lane 5), whereas DNA containing the mutant
E21 sequence did not compete (18) (lane 6).
To test whether BCF1 and BCF2 can interact with the
E2-box sequences present in the heavy-chain and kappa
light-chain enhancer, nuclear extracts from WEHI 231 were
incubated with probes containing the KE2 (GGCAGGTGG)
(22) and 1LE5 (TGCAGGTGT) sites. Both KE2 and ,uE5 are
crucial for immunoglobulin heavy- and light-chain gene
expression (19). BCF complexes bind to ,uE5 (Fig. 1C, lane
BCF1 -
BCF2 -
VOL. 1l, 19911158 MURRE ET AL.
ExtrOct C2C12
(Myocytes)
Seran- I C
WEHI 231
(Moture B Cell)
- I C
HELA
- I C
Extract Ba/F3 LyD9PD31 WEHI
(pro)(o) (pre)(moture)
BCFi-
,- V
BCF2- w
MEF-fl $10
-NS
I
1 2 3 4 5 6 7 8 9
FIG. 2. Components of B-cell- and muscle-specific E2-box
DNA-binding complexes are antigenically related to E12/E47 pro-
teins. Lanes: 1, muscle (C2C12) nuclear extracts incubated in the
absence ofantiserum; 2, muscle extract incubated in the presence of
anti-E12/E47 antiserum; 3, muscle extract incubated in the presence
ofpreimmune antiserum; 4, B-cell extract incubated in the absence
ofantiserum; 5, B-cell extract incubated in the presence ofanti-E12/
E47 antiserum; 6, B-cell extract incubated in the presence of
preimmune serum; 7, HeLa extract incubated in the absence of
antiserum; 8, HeLa extract incubated in the presence of anti-E12/
E47 serum; 9, HeLa extract incubated in the presence ofpreimmune
serum. MEF, Muscle-specific complexes; NS, nonspecific DNA-
binding proteins.
3) with high affinity, but binding to the KE2 site was weaker
and qualitatively different (lane 2). The faster-migrating
complex binding to the KE2 site was nonspecific. Thus, BCF
complexes bind to sequences that are important for immu-
noglobulin heavy- and light-chain gene expression (17, 19).
B-cell-specific E2-box DNA-binding complexes contain E12/
E47-like subunits. E47 protein can transactivate a reporter
gene containing multiple ,uE5 and KE2 sequences positioned
5' of its promoter (16, 29a), suggesting that E47 is part of a
transcriptional complex binding to the ,uE5 and KE2 motifs.
To test whether the BCF complexes contain E12/E47 mole-
cules, B-cell nuclear extracts derived from WEHI 231 were
incubated with anti-E12/E47 antiserum and assayed by
EMSA. The antiserum does not recognize determinants
present in the conserved HLH motifor determinants present
in other related HLH proteins, for example MyoD, Id, and
myogenin among the tested molecules (1, 21, 31). Thus, it is
specific for E12 and E47 polypeptides, although we cannot
exclude the possibility that other closely related polypep-
tides share determinants with E12/E47. The anti-E12/E47
antibody, however, does not distinguish between E12 and
E47 polypeptides (21). Both the BCF1 and BCF2 complexes
supershifted (migrated more slowly) in the presence of the
anti-E12/E47 antibody (Fig. 2, lane 5), whereas preimmune
serum did not affect complex mobility (lane 6). Thus, BCF1
and BCF2 contain E47- and/or E12-like molecules.
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FIG. 3. B-cell-specific E2-box DNA-binding factors are present
in pre-B and mature B cells but not in pro-B cell lines. Nuclear
extract from various B-cell lines representing various stages of
B-cell development were analyzed by EMSA with the muscle
creatine kinase E2-box as a probe. Lanes: 1, nuclear extract derived
from the pro-B cell line Ba/F3; 2, nuclear extract derived from the
pro-B cell line LyD9 (13); 3, nuclear extract derived from the pre-B
cell line PD31; 4, nuclear extract derived from the mature B-cell line
WEHI 231. Only the region ofthe gel containing the shifted probe is
shown.
BCF1 andBCF2 are present in pre-B and mature B cells but
not in pro-B cells. To determine at what stages of B-cell
development BCF1 and BCF2 are present, nuclear extracts
derived from different B-cell lines were examined by EMSA
with the E2-box, derived from the muscle creatine kinase
enhancer, as a probe. Both BCF1 and BCF2 were detected
in pre-B-cell and mature B-cell lines (Fig. 3, lanes 3 and 4),
but not in pro-B-cell lines (a kind gift ofR. Palacios) (lanes 1
and 2) (27). We have examined fouradditional pre-B-cell and
mature B-cell lines; they all contain the B-cell-specific BCF1
and BCF2 complexes (data not shown). The faster-migrating
band present in pro-B cells is nonspecific (20a). Mature B
and pre-B-cell lines, but not the pro-B-cell lines examined
here, express immunoglobulin heavy chain. The presence of
BCF1 and BCF2 therefore correlates with immunoglobulin
heavy-chain gene expression.
Myocyte-specific E2-boxDNA-binding proteins contain E12/
E47-like subunits. Previously we have shown that E12 and
E47 proteins can interact with MyoD in vitro to form
heterodimers that bind to the E2-box motif (21). Myocyte
nuclear extracts contain muscle-specific complexes that are
identical or antigenically related to MyoD and myogenin
(18). To determine whether E12/E47-like proteins form het-
erodimers with MyoD and myogenin in vivo, myocyte
nuclear extracts were incubated with an anti-E12/E47 anti-
body and analyzed by EMSA. The muscle-specific com-
plexes reacted with the antibody (Fig. 2, lane 2) but not with
preimmune serum (lane 3). Thus, myocyte-specific com-
plexes contain E12/E47 molecules or ones closely related to
E12/E47.
BCF complexes comigrate with homo-oligomers ofE47 in an
EMSA. Although the anti-E12/E47 antibody did react with
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FIG. 4. BCF1 and BCF2 proteins comigrate in an EMSA with
homo-oligomers of E47. BCF1 and BCF2 were analyzed by EMSA
and compared in vitro and in vivo by using a radiolabeled muscle
creatine kinase E2-box as a probe. Lanes: 1, in vitro-translated E47;
2, nuclear extract derived from a pre-B cell line, PD31; 3, nuclear
extract derived from HeLa cells; 4, nuclear extract derived from
HeLa cells transiently transfected with an E47 cDNA placed under
the control of the cytomegalovirus promoter. F, Probe not bound to
protein.
the muscle-specific complexes, the relative ability of the
antiserum to supershift the complexes was 100-fold lower for
the muscle-specific complexes than for the BCF proteins
(20a). A trivial explanation for this difference in affinity could
be that BCF1 and BCF2 are homo-oligomers ofE12/E47. To
address this issue, we have examined the relative affinity of
the anti-E12/E47 antibody for in vitro-synthesized E47
homo-oligomers and E47-MyoD heterodimers. E47 homo-
oligomers have a 100-fold-higher affinity for the antibody
than do E47-MyoD heterodimers (20a). In addition, in vitro-
translated full-length E47 generated two complexes that
comigrated with the BCF1 and BCF2 complexes present in
nuclear extracts frotn a pre-B-cell line, PD31 (Fig. 4, lanes 1
and 2). Why the in vitro E47-synthesized molecules generate
two complexes with different mobilities in an EMSA is not
clear. They either could represent variable complexes of
E47, for example a dimer (BCF2) and a tetramer (BCF1), or
could result from posttranslational modification. To deter-
mine whether the product of E47 cDNA migrates with
similar mobility' when expressed in vivo, a full-length E47
cDNA placed under the control of the cytomegalovirus
promoter was introduced transiently into HeLa cells. Nu-
clear extracts derived from HeLa cells transfected with E47
cDNA were then examined by EMSA. Two complexes were
apparent in the extracts prepared from the transfected cells
but not from the control cells. These complexes comigrated
exactly with BCF1 and BCF2 (Fig. 4, lanes 3 and 4) and were
supershifted by the anti-E12/E47 antibody (data not shown).
These data suggest that the BCF proteins might consist of
oligomers of E47 or E12 or a closely related protein. In
addition, in vitro-translated E47 polypeptide and BCF pro-
teins have very similar affinities to anti-E12fE47 antibody
(20a), which further supports the idea that the BCF proteins
are indeed oligomers ofE12 or E47. It is unlikely that BCF1
and BCF2 represent homo-oligomers of E12, because E12
homo-oligomers have a relatively weak affinity for the E2
sequence under the conditions described here (22). Thus,
BCF1 and BCF2 most probably represent homo-oligomers
of E47 or hetero-oligomers containing E12 and E47. We
note, however, that further analysis of these complexes is
required to exclude the possibility that a B-cell-specific
polypeptide associates with E47 or E12 in BCF1 and BCF2.
DISCUSSION
We have presented data showing that both myocyte and
B-cell E2-box DNA-binding proteins contain E12/E47-like
subunits. In B-cell nuclear extracts, complexes containing
E47 subunits-very probably consisting ofa homo-oligomer
of E47-are present that cannot be detected in non-B cells.
E12 and E47 mRNA has been detected in all cell types
examined (22). We have immunoprecipitated E12/E47 poly-
peptides from Jurkat and HeLacells (20a). Why are apparent
E47 homo-oligomers detected in nuclear extracts derived
from B cells but not in those of other cell types? One
possibility is that in many cells E47 polypeptides are com-
plexed with other HLH polypeptides, such as Id, that would
inhibit their DNA binding (1). Id was shown to form het-
erodimers with E47 in vitro, inactivating its ability to bind to
DNA. Id levels are low in differentiated cell types, whereas
they are high in undifferentiated cells (1). High levels of Id
might inhibit the DNA-binding activity or HLH proteins
such as E47. In pro-B and other cell types, levels of
inhibitory molecules identical or related to Id might be high,
preventing E47 from forming homo-oligomers (24a). During
B-cell differentiation, similarly to myogenesis, levels of such
inhibitory molecules might drop, allowing E47 polypeptides
to form oligomers that can now bind to regulatory sequences
present in the immunoglobulin heavy- and light-chain gene
enhancers, inducing their transcription and subsequently
B-cell differentiation. In other cells, the presence of class B
HLH proteins such as MyoD would lead to preferential
heterodimer formation (26b) and suppress the homo-oligo-
mers.
These data suggest that the role ofE12/E47-like proteins in
mammalian development might be similar to that of da in
Drosophila. da is a gene whose various mutants show
pleiotropic effects. da controls both sex determination and
neurogenesis (9). A role for da in other developmental
pathways is likely, but evidence is lacking because of the
lethality ofda mutations. The physical similarity between da
and E12/E47 proteins is striking. The E12/E47 sequences are
as related to da in the region surrounding the HLH region as
they are to each other (22). In addition, each of the proteins
is ubiquitously expressed. In this paper we present data
suggesting a role for E12/E47-like proteins in myogenesis
and B-cell development. A role for E12/E47 proteins in
pancreatic p-cell differentiation is likely as well. The E2-box
sequence is present in the insulin enhancer, a site that has
been shown to be crucial for its tissue-specific expression
(20, 24). Indeed, Stein and collaborators recently found that
a p-cell-specific complex that binds the E2-box is super-
shifted with an anti-E12/E47 antibody (26a, 30). They also
found that the activity ofthe E2 regulatory sequence present
in the insulin enhancer is responsive to Id. Thus, E12/E47
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and related molecules may well function in controlling
development by associating either with tissue-specific com-
ponents, such as MyoD in MEF-1, or as homo-oligomers
in the BCF proteins, inducing the differentiated-muscle-,
B-cell-, and P-cell-specific phenotypes.
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